Key result
Oral propranolol yields wide pharmacokinetic variability in hypertensive patients, with effective absorption averaging ~46%.
Why the study?
There was marked interpatient variation in plasma propranolol concentrations during therapy, primarily due to differences in effective absorption of the drug.
Observational
Propranolol exhibits marked interpatient variability in absorption, and its pharmacokinetic profile supports specific intravenous dosing guidelines (8 mg loading dose, 0.02 mg/min sustaining dose).
Answers are grounded in this paper and cite their sources.
Absorption variability supports cautious propranolol dosing; leaves open optimal monitoring strategies in practice.
The variability of plasma propranolol concentrations has been determined in a large group of patients being treated with the drug. Although the average patient achieved a therapeutic plasma level with 160 mg/day, there was marked interpatient variation. This was found to be primarily the result of differences in effective absorption of the drug, which averaged 46% of the oral dose but ranged from 20 to 80%. Propranolol disappeared from plasma with a half-life of 4.7 hours and its removal appeared to follow dose independent kinetics with no evidence of saturation of hepatic metabolism. The derived pharmacokinetic values of volume of distribution and clearance rate have been used to provide guidelines for initiating propranolol therapy intravenously, and the schedule of 8 mg as a loading dose and 0.02 mg/min as a sustaining dose has been suggested.
No takes yet. Share an insight, caveat, or question.
Chidsey et al. (1975) conducted an observational in Hypertension. Propranolol was evaluated on Pharmacokinetic variability (effective absorption and half-life). Oral propranolol absorption averaged 46% with marked interpatient variation and a half-life of 4.7 hours in hypertensive patients.
Synapse has enriched 10 related papers. Consider them for comparative context: